Infliximab treatment for rheumatic disease: Clinical and radiological efficacy


Conference Paper

Infliximab is a chimeric anti-tumour necrosis factor α (TNFα) monoclonal antibody with high affinity and binding specificity for human TNFα. Results from several well designed, controlled clinical trials show repeated infusions of infliximab with concomitant methotrexate (MTX) treatment can reduce the signs and symptoms of rheumatoid arthritis (RA). This combination of infliximab and MTX also slows the radiological progression of joint damage, decreases functional disability, and improves qualify of life. These remarkably positive results have led to the investigation of infliximab treatment for other rheumatic diseases. Recently, controlled studies have shown treatment with infliximab can benefit patients with active spondyloarthropathy. TNFα has fast become an important therapeutic target in rheumatology.

Duke Authors

Cited Authors

  • St Clair, EW

Published Date

  • November 1, 2002

Published In

Volume / Issue

  • 61 / SUPPL. 2

International Standard Serial Number (ISSN)

  • 0003-4967

Citation Source

  • Scopus